WeWork Announces Date of First Quarter 2023 Results Conference Call
Get Alerts WE Hot Sheet
Join SI Premium – FREE
NEW YORK--(BUSINESS WIRE)-- WeWork Inc. (NYSE: WE) (“WeWork”), the leading global flexible space provider, today announced that on Tuesday, May 9, 2023, it will issue financial results for the first quarter ending March 31, 2023. The company will conduct a conference call at 8:00 AM ET, following the release of its earnings materials.
Earnings call details, the company’s earnings release, and related materials will be available on WeWork’s Investor Relations website at investors.wework.com. A replay of the conference call will be available at the same website after the call.
WeWork announces material information to the public through a variety of means, including filings with the Securities and Exchange Commission, press releases, public conference calls, webcasts and the investor relations section of its website (investors.wework.com) in order to achieve broad, non-exclusionary distribution of information to the public and for complying with its disclosure obligations under Regulation FD.
About WeWork:
WeWork (NYSE: WE) was founded in 2010 with the vision to create environments where people and companies come together and do their best work. Since then, we’ve become one of the leading global flexible space providers committed to delivering technology-driven turnkey solutions, flexible spaces, and community experiences. For more information about WeWork, please visit us at wework.com.
Source: We Work
Category: Investor Relations
View source version on businesswire.com: https://www.businesswire.com/news/home/20230411005454/en/
Investor Relations:
Kevin Berry
[email protected]
Press:
Nicole Sizemore
[email protected]
Source: We Work
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fisker (FSRN) Unable to Timely File 10-Q, Auditor Resigns, Reiterates Going Concern Doubts
- Lee Kum Kee Sponsors the 9th World Championship of Chinese Cuisine
- Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track S
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!